Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200GlobeNewsWire • Monday
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket TrialGlobeNewsWire • 08/25/26
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket TrialGlobeNewsWire • 05/28/26
Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals AwardsGlobeNewsWire • 05/14/26
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family ConferenceGlobeNewsWire • 04/23/26
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket TrialGlobeNewsWire • 04/21/26
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric CareGlobeNewsWire • 04/15/26
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/01/26
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)GlobeNewsWire • 03/17/26
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy EventsGlobeNewsWire • 03/12/26
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage DisordersGlobeNewsWire • 02/27/26
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket TrialGlobeNewsWire • 02/17/26
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™GlobeNewsWire • 02/10/26
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial LaunchGlobeNewsWire • 02/03/26
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”GlobeNewsWire • 02/02/26